DK3692040T3 - Kemiske forbindelser - Google Patents

Kemiske forbindelser Download PDF

Info

Publication number
DK3692040T3
DK3692040T3 DK18795809.5T DK18795809T DK3692040T3 DK 3692040 T3 DK3692040 T3 DK 3692040T3 DK 18795809 T DK18795809 T DK 18795809T DK 3692040 T3 DK3692040 T3 DK 3692040T3
Authority
DK
Denmark
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
DK18795809.5T
Other languages
English (en)
Inventor
John G Catalano
Pek Yoke Chong
Hamilton D Dickson
Martin R Leivers
Jason Gordon Weatherhead
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3692040T3 publication Critical patent/DK3692040T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18795809.5T 2017-10-05 2018-10-05 Kemiske forbindelser DK3692040T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568633P 2017-10-05 2017-10-05
US201762570509P 2017-10-10 2017-10-10
US201862681146P 2018-06-06 2018-06-06
US201862683859P 2018-06-12 2018-06-12
PCT/IB2018/057767 WO2019069293A1 (en) 2017-10-05 2018-10-05 CHEMICAL COMPOUNDS

Publications (1)

Publication Number Publication Date
DK3692040T3 true DK3692040T3 (da) 2023-03-13

Family

ID=64049476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18795809.5T DK3692040T3 (da) 2017-10-05 2018-10-05 Kemiske forbindelser

Country Status (27)

Country Link
US (3) US20200255428A1 (da)
EP (2) EP4180431A1 (da)
JP (1) JP7248665B2 (da)
KR (1) KR102705376B1 (da)
CN (2) CN111433206B (da)
AU (2) AU2018344926A1 (da)
CA (1) CA3078312A1 (da)
CL (1) CL2020000912A1 (da)
CO (1) CO2020004202A2 (da)
CY (1) CY1125888T1 (da)
DK (1) DK3692040T3 (da)
ES (1) ES2940263T3 (da)
FI (1) FI3692040T3 (da)
HR (1) HRP20230274T1 (da)
HU (1) HUE061380T2 (da)
IL (1) IL273769B2 (da)
LT (1) LT3692040T (da)
MX (1) MX2020003382A (da)
MY (1) MY201605A (da)
PH (1) PH12020550145A1 (da)
PL (1) PL3692040T3 (da)
PT (1) PT3692040T (da)
RS (1) RS64043B1 (da)
SG (2) SG10202111648YA (da)
SI (1) SI3692040T1 (da)
SM (1) SMT202300089T1 (da)
WO (1) WO2019069293A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
CN116751200A (zh) * 2016-11-07 2023-09-15 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019233941A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease
WO2019246427A1 (en) * 2018-06-22 2019-12-26 Arbutus Biopharma Corporation Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
US12128044B2 (en) 2018-08-28 2024-10-29 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
CA3113235A1 (en) 2018-09-21 2020-03-26 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
CN111217811B (zh) * 2018-11-26 2024-01-16 广东东阳光药业股份有限公司 稠合三环类化合物及其在药物中的应用
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN113173911A (zh) * 2021-04-20 2021-07-27 梯尔希(南京)药物研发有限公司 吡虫啉代谢物5-羟基吡虫啉的合成方法
KR20240144245A (ko) 2022-01-28 2024-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 B형 간염 바이러스 감염을 치료하기 위한 조합 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504633A (ja) * 2014-01-30 2017-02-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft B型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
CA2948080A1 (en) * 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) * 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
EP3256471B1 (en) * 2015-02-11 2018-12-12 F. Hoffmann-La Roche AG Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017108630A1 (en) * 2015-12-21 2017-06-29 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor
TW201811788A (zh) * 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
CN116751200A (zh) * 2016-11-07 2023-09-15 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
CN106810548B (zh) * 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物
CN108727378A (zh) * 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途

Also Published As

Publication number Publication date
MX2020003382A (es) 2020-10-05
HUE061380T2 (hu) 2023-06-28
AU2021203650B9 (en) 2022-10-06
EP4180431A1 (en) 2023-05-17
KR102705376B1 (ko) 2024-09-11
WO2019069293A1 (en) 2019-04-11
AU2021203650B2 (en) 2022-09-08
IL273769A (en) 2020-05-31
CN111433206A (zh) 2020-07-17
IL273769B1 (en) 2025-03-01
SG11202002771XA (en) 2020-04-29
SI3692040T1 (sl) 2023-05-31
CA3078312A1 (en) 2019-04-11
KR20200065024A (ko) 2020-06-08
CN111433206B (zh) 2023-07-07
HRP20230274T1 (hr) 2023-04-28
SG10202111648YA (en) 2021-11-29
ES2940263T3 (es) 2023-05-04
AU2018344926A1 (en) 2020-04-16
US12221444B2 (en) 2025-02-11
BR112020006456A2 (pt) 2020-10-06
MY201605A (en) 2024-03-05
EP3692040A1 (en) 2020-08-12
PT3692040T (pt) 2023-04-03
CO2020004202A2 (es) 2020-04-24
LT3692040T (lt) 2023-04-25
US20200255428A1 (en) 2020-08-13
FI3692040T3 (fi) 2023-03-29
RU2020118375A3 (da) 2022-04-13
IL273769B2 (en) 2025-07-01
CY1125888T1 (el) 2026-02-25
AU2021203650A1 (en) 2021-07-01
RU2020118375A (ru) 2021-11-09
JP7248665B2 (ja) 2023-03-29
PL3692040T3 (pl) 2023-04-17
EP3692040B1 (en) 2022-12-28
US20220144834A1 (en) 2022-05-12
SMT202300089T1 (it) 2023-05-12
CN116942663A (zh) 2023-10-27
PH12020550145A1 (en) 2021-01-04
RS64043B1 (sr) 2023-04-28
JP2020536110A (ja) 2020-12-10
CL2020000912A1 (es) 2021-02-19
US20250066361A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
SMT202300089T1 (it) Composti chimici
IL286839A (en) Propyne-indole compounds
PL3844147T3 (pl) Związki chemiczne
IL272249A (en) Organic compounds
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3668855T3 (da) Herbicide forbindelser
DK3519420T3 (da) Cykliske dinukleotidforbindelser
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
LT3297998T (lt) Priešgrybeliniai junginiai
IL262335A (en) Stable nimopidine parenteral formulation
CL2016002129A1 (es) Compuestos de azolina
PT3298027T (pt) Compostos depsipéptidos antelmínticos
LT4101855T (lt) Priešnavikiniai junginiai
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
LT3464336T (lt) Junginiai
BR112017017193A2 (pt) compostos herbicidas
LT3362444T (lt) Junginiai
IL268652B (en) Chemical composition
EP3533799A4 (en) CONNECTION
EP3438103A4 (en) Griseofulvin compound
DK3597189T3 (da) Krystallinske forbindelser
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu
DK3672941T3 (da) Pyridylpyridonforbindelser
DK3347403T3 (da) Polyalkoxyfedtforbindelse
LT3668879T (lt) Nauji junginiai